Treatment options for patients with myeloma who relapse after allogeneic stem cell transplantation are limited. Thalidomide, an antineoplastic agent, has been shown to be effective in multiple myeloma through proposed mechanisms that may include angiogenesis inhibition. Herein we report successful thalidomide treatment of four patients who relapsed following allogeneic transplantation, three of whom had predominantly extramedullary relapse. Thalidomide was well tolerated in all patients; in two patients interferon-␣ was subsequently added to thalidomide as maintenance therapy without worsening graft-versus-host disease. We suggest that extramedullary myeloma is particularly sensitive to thalidomide, speculating that growth biology may in part be dependent on angiogenesis. Bone Marrow Transplantation (2001) 28, 1145-1150. Keywords: myeloma; thalidomide; transplantation; extramedullary; allogeneic; graft-versus-host disease Management options for multiple myeloma (MM) include autologous stem cell transplantation (autoSCT) and allogeneic bone marrow/stem cell transplantation (alloBMT).
Management options for multiple myeloma (MM) include autologous stem cell transplantation (autoSCT) and allogeneic bone marrow/stem cell transplantation (alloBMT). [1] [2] [3] Following alloBMT, a graft-versus-myeloma (GVM) effect is well recognized and may contribute to sustained molecular remission. [4] [5] [6] However, treatment options for relapse following alloBMT are often limited by concomitant graft-versus-host disease (GVHD), hematologic cytopenias or poor performance status.
Thalidomide has antineoplastic properties, through proposed mechanisms that include angiogenesis inhibition, immunomodulation, apoptotic mechanisms, and modulation of T cell function. [7] [8] [9] [10] In myeloma, angiogenesis as measured by microvessel density (MVD) has correlated with disease activity and outcome. [11] [12] [13] There is also recent evidence that thalidomide is active in vitro against MM cell lines resistant to standard chemotherapy.
14 Recently pub- lished studies have demonstrated activity of thalidomide in relapsed or refractory MM, [15] [16] [17] including patients who had had autoSCT. 18 To date there are no published data specifically examining the role of thalidomide for relapse after alloBMT.
Trials investigating the role of interferon-␣ (IFN) in induction and maintenance phases of disease have yielded conflicting results. A recent meta-analysis demonstrated a survival advantage in this setting, suggesting that maintenance therapy may be of benefit. 19 We have concluded a clinical trial evaluating the efficacy of thalidomide, with IFN as maintenance treatment, in the management of relapsed or refractory MM. Four of the 75 patients accrued relapsed after HLA-identical sibling alloBMT. Herein we report successful thalidomide treatment in these four patients, three of whom had predominantly extramedullary (EM) relapse. Furthermore, we describe two of these patients who have proceeded to IFN maintenance therapy while on thalidomide. Issues related to EM relapse and the effects of the combination of thalidomide and IFN on disease control and GVHD are discussed.
Study design of thalidomide trial
Patients were prospectively enrolled into a phase II study of thalidomide for progressive or refractory MM requiring systemic therapy, including patients who may have undergone autoSCT or alloBMT. Eligibility criteria included age у18 and an ECOG performance 0-2. Pregnant or lactating women were excluded, and all men and women of childbearing age used adequate contraception. Patients were not excluded for abnormal renal, hepatic or hematopoietic parameters. Responses were defined such that a partial response (PR) required a greater than 50% reduction in serum Mprotein and/or, Bence-Jones proteinuria (BJP), and/or in the size of plasmacytomata or marrow plasma cell infiltrate. 20 The primary endpoint was response rate, with secondary endpoints of event-free survival, overall survival, toxicity of thalidomide, and tolerability of thalidomide combined with IFN. /l and platelets у75 × 10 9 /l. The initial dose was 3 million units subcutaneously thrice weekly and was continued while PR or stable disease (SD) was maintained. IFN was dose-reduced due to side-effects and both thalidomide and IFN were discontinued at the time of disease progression.
As per protocol, a clinical assessment and blood tests were completed every 2 weeks on all study patients. Nerve conduction studies (NCS) were performed at enrollment and every 3 months to monitor for peripheral neuropathy, a potential side-effect of thalidomide.
Case reports

Case 1
This man was 42 years old when diagnosed with stage III myeloma, presenting as kappa light chain BJP and diffuse, symptomatic skeletal disease. He achieved a PR following local radiotherapy and 8 months of intermittent melphalan and prednisolone, and then proceeded to a matched-sibling alloBMT with busulphan and cyclophosphamide conditioning. Subsequent GVHD, manifested by elevation of liver enzymes, oral ulcers and diarrhoea, required 3 years of lowdose immunosuppression that was successfully discontinued.
After a 4-year disease-free interval, he developed diffuse axial and peripheral lytic bone disease, BJP of 0.17 g/l and a 4 cm extramedullary right-sided gastrocnemius plasmacytoma ( Figure 1 ), with bone marrow demonstrating a 25% plasmacytosis. Following treatment for 8 weeks on an escalating dose of thalidomide to 800 mg, there was a marked reduction in the plasmacytoma to Ͻ2 cm and marrow infiltration to 5%. The liver enzymes, which had been chronically elevated due to GVHD prior to thalidomide therapy, returned to normal, suggesting a possible anti-GVHD effect of thalidomide. Initiation of IFN was delayed due to a transient neutropenia. Stable disease was achieved on thalidomide for 11 months, combined with IFN at full dose for 7 months, before the patient relapsed with proteinuria and bony disease. At no point during this time was there clinical or biochemical evidence of GVHD reactivation. There was no progression of the plasmacytoma while on thalidomide.
Case 2
This man initially presented at the age of 49 with a plasmacytoma of the right mandible. Investigations revealed a serum IgA lambda paraprotein, and a 30% marrow plasmacytosis. After a poor response to initial multi-agent systemic chemotherapy, he underwent a matched-sibling alloBMT with melphalan and total body irradiation (TBI) conditioning, with no subsequent GVHD. After a 3-year disease-free interval, he developed a lumbar soft-tissue plasmacytoma. Treatment with three courses of donor lymphocyte infusion (DLI) caused regression of the plasmacytoma, but resulted in chronic mild-moderate GVHD of liver and lungs, which required cyclosporine and prednisolone immunosuppression. Subsequent plasmacytomata in the skull bones responded to local radiotherapy plus intravenous melphalan over the next 2 years. Immunosuppressive therapy was successfully tapered to a low dose of daily steroid.
On enrollment to the thalidomide trial, his only site of disease was a newly developed isolated plasmacytoma of the left infra-temporal fossa measuring 2.5 × 2 cm (Figure 2) . No serum or urine paraprotein was detected, and the marrow was normal with 100% of cells being of donor origin. After 3 months on thalidomide at a dose of 400 mg/day, the plasmacytoma resolved. He remains in CR after 7 months. Thalidomide dose escalation and initiation of IFN have not been possible due to ongoing fatigue, somnolence, and moderate GVHD-related bronchiolitis obliterans. 
Case 3
This man was 39 years old when he presented in 1996 with stage III MM, consisting of moderate renal insufficiency (creatinine 1.5× upper limit of normal) and BJP. A bone marrow biopsy revealed 50% plasma cell involvement. There was only a minor response to six cycles of PCAB (prednisolone, cyclophosphamide, doxorubicin, carmustine) chemotherapy. He proceeded 1 year later to matched-sibling alloBMT, achieving a PR, with a residual marrow plasmacytosis of 15% and absent BJP. No significant GVHD developed.
IFN maintenance was used for 6 months, but then discontinued because of significant fatigue. He remained in PR for 3 years, but progressed with symptomatic spinal cord compression at T4. A good clinical response was obtained with local radiation. Restaging investigations at this time revealed patchy axial skeletal disease on MRI,
Bone Marrow Transplantation and a urine paraprotein of 3.5 g/24 h. The bone marrow contained 50% plasma cell infiltration.
After 5 months of thalidomide at 800 mg/day, the patient achieved a PR with substantial resolution of proteinuria to 0.81 g/24 h, a modest decrease of marrow plasmacytosis to 40%, and stable cortical bone disease. Tolerance of thalidomide has been good, and there continues to be no evidence of GVHD. He was subsequently started on IFN, which he tolerated well at 1.5 million units subcutaneously thrice weekly over 5 months at last follow-up.
Case 4
This woman was 45 years of age when she presented with stage III disease, including a pathological fracture, multiple lytic bony lesions, hypercalcemia, 80% marrow plasmacytosis, urinary kappa light chain proteinuria of 6 g/24 h, and normal serum electrophoresis. Treatment with multiagent PCAB resulted in a good PR, and was followed by matched-sibling alloBMT with high-dose cyclophosphamide and TBI conditioning. Acute but mild gut and hepatic GVHD developed on day 27. Prednisolone and cyclosporine immunosuppression was required for 11 months, and upon cessation there was no further evidence of GVHD.
Three years later the patient developed a biopsy-proven T3 paraspinal recurrence and an additional lesion in the region of the left scapula on MRI and PET scan. Treatment with local spinal irradiation and pulse dexamethasone achieved symptomatic relief. However, PET scan 4 months later demonstrated residual activity at both the spinal and scapular sites. The bone marrow contained 5% plasma cells. There was no serum paraprotein and only a trace of BJP detected.
The patient reached a maximum dose of 300 mg/day thalidomide, limited by tremors and fatigue. After 4 months, the PET scan became negative at both sites while bone marrow plasmacytosis and urinary paraprotein remained stable. Interferon has not been introduced because of ongoing fatigue. There has been no evidence of clinical GVHD.
Cytogenetics on the four patients revealed no chromosomal abnormalities. Chimerism was evaluated by previously described methods, without analysis of myeloid or T cell subsets. 21 A summary of patient characteristics is presented in Table 1 .
A core biopsy specimen of a plasmacytoma from case 2 was assessed for microvessel density (MVD), by standard immunohistochemical stains for von Willebrand factor (Figure 3) . 22, 23 Tissue from the two other patients with EM relapse was not available for staining. A mean MVD count of 97 counts/field was determined from three hot spots at a magnification of ×400.
Discussion
This report is, to our knowledge, the first to specifically document successful treatment with thalidomide in the post-alloBMT setting. We also describe the first reported use of IFN as maintenance therapy in combination with thalidomide. Extramedullary relapse, occurring either as an isolated phenomenon or concurrent with systemic relapse, has been reported in case series following allogeneic and autologous transplantation. [24] [25] [26] [27] [28] [29] Of the four patients in our study who underwent alloBMT, three subsequently relapsed with EM disease, which responded in all three cases to thalidomide. It is also of interest that in case 1, the relapse while on thalidomide, did not involve EM disease.
Microvessel density has been utilized as a measure of angiogenesis in marrow and solid tissue. In this study we measured MVD in the one available specimen (case 2, Figure 3 ). Indeed, the measured MVD of 97 counts/field is similar, if not higher, than that demonstrated in previously published reports of the increased marrow MVD in active myeloma 12, 30 and solid tumors such as invasive breast cancer. 22 Although comparison of MVD between different studies and tissue types must be interpreted with caution we believe this observation warrants further investigation.
The consistent responses of plasmacytomata and discordant response/relapse patterns reported here suggest that thalidomide may be particularly effective in the treatment of plasmacytomata compared to non-EM disease. The role of angiogenesis in thalidomide's mechanism of action remains controversial, especially in light of the observation that bone marrow MVD may not decrease in responding patients. 15 Alternative explanations for the effectiveness of thalidomide in EM disease may be related to differences in growth biology, such as selection of genetically distinct clones that develop after chemotherapy, and different growth stimuli at EM sites compared to bone marrow. 25, 28, 31, 32 Significant side-effects of thalidomide were limited to fatigue in two patients who did not tolerate dose escalation above 400 mg/day, and for whom initiation of IFN was precluded. None of the patients developed significant alterations in nerve conduction. In one patient with elevated liver enzymes secondary to chronic GVHD, treatment with thalidomide normalized the liver profile, consistent with its recognized efficacy in the control of acute and chronic GVHD. 33, 34 Although the underlying mechanism remains unclear, the effects may be related to its immunomodulatory effects on T cell function. 9, 10 This same patient also tolerated concomitant IFN maintenance without exacerbation of his GVHD, which was a potential concern as IFN may exacerbate GVHD. 35, 36 Thus, we would now not consider chronic GVHD a contraindication to thalidomide and IFN in selected patients. A cautionary note, however, is that we have not added IFN to thalidomide in patients who have persistent active GVHD while on thalidomide.
Following alloBMT or DLI, GVHD is often used as a surrogate indicator that a GVM effect is induced. Nonetheless, it remains unclear whether GVH and GVM effects are co-dependent in the control of MM, as responses do occur in the absence of clinical GVHD. [37] [38] [39] Regardless, we think it unlikely that induction of GVM was responsible for disease regression in our patients, as two patients had preexisting chronic GVHD at relapse, and none had exacerbation of GVHD while on study. These observations are further supported by a report from Zomas et al, 25 in which plasmacytomas developed independent of significant GVHD following DLI.
In summary, our preliminary experience suggests that thalidomide is an effective treatment option in patients with myeloma who relapse after an allogeneic transplant, and may be particularly effective if the relapse includes EM sites. Furthermore, the combination of thalidomide and IFN may be incorporated in the post-alloBMT setting even in the presence of chronic GVHD.
